The Investigational Multi-Targeted Kinase Inhibitor TAK-901 Antagonizes Acute Myeloid Leukemia Pathogenesis: Results of Preclinical Studies
Patrick R. Griffin(The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology), Jennifer S. Carew(University of Arizona), Ron de Jong(Takeda (United States)), Claudia M. Espitia(The University of Texas System), Steffan T. Nawrocki(University of Arizona), Angela Romanelli(Centre National de la Recherche Scientifique), Maki Hasegawa(Takeda (Japan)), Takashi Satou(Takeda (Japan)), Kevin R. Kelly(Keck Hospital of USC)
Cited by 1
Related Papers
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782
Role for Akt3/Protein Kinase Bγ in Attainment of Normal Brain Size
|Molecular and Cellular Biology|2005|549